8-K: Aditxt Amends Note Purchase Agreement, Adds Investor

Aditxt, Inc. has amended its Note Purchase Agreement, adding a new investor and issuing additional senior secured notes while canceling an existing note, maintaining the aggregate principal amount.

Summary

• Aditxt, Inc. (the Company) has entered into Amendment No. 2 to its Note Purchase Agreement, originally dated June 3, 2026.
• This amendment allows a new investor to join the agreement.
• It also cancels one previously issued Note and issues two new Additional Notes.
• The aggregate principal amount of senior secured notes remains unchanged.
• The Additional Notes, along with previously issued Notes, are secured by substantially all assets of Ignite Proteomics LLC and pledged equity of Ignite by the Company.
• The transaction is exempt from registration requirements under the Securities Act of 1933, pursuant to Section 4(a)(2) and Regulation D.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it involves a restructuring of existing debt with no net change in principal amount, but does bring in a new investor and cancel an old note.

Positives

• Successfully onboarded a new investor into the existing financing agreement.
• Maintained the aggregate principal amount of senior secured notes, indicating no net increase in debt.
• Secured the notes with a comprehensive collateral package including substantially all assets of a subsidiary and pledged equity.
• The transaction is structured to be exempt from registration, streamlining the process.

Negatives

• The need for further amendments and the issuance of new notes suggests ongoing financing needs.
• Cancellation of an existing note and issuance of new ones may indicate restructuring or changes in investor participation.
• The company is relying on private placements (Regulation D) for financing, which can be more restrictive than public offerings.

Risks

• Forward-looking statements are subject to risks and uncertainties, including the completion of sales under the Purchase Agreement and proceeds received.
• Other risk factors are more fully discussed in the Company's filings with the SEC.

Future Outlook

The filing contains forward-looking statements regarding the Company's strategy and future plans, which are subject to risks and uncertainties that could cause actual results to differ materially.

Industry Context

StockSavvy.ai notes that amendments to financing agreements and the addition of new investors are common for companies in development stages or those requiring ongoing capital to fund operations and growth initiatives. The use of private placements suggests a strategic approach to capital raising, potentially to avoid immediate public market scrutiny or dilution.

Stakeholder Impact

• Shareholders: The amendment and issuance of notes may impact equity dilution depending on the terms of the notes and future conversion rights, though the aggregate principal amount remains unchanged.
• Creditors: The security interest granted to the noteholders over Ignite's assets and the Company's equity in Ignite strengthens the position of these creditors.
• Investors: A new investor is added to the Note Purchase Agreement, and an existing investor's note is cancelled and replaced.

Next Steps

• The Borrowers shall file a Current Report on Form 8-K with the SEC describing the terms of the transactions contemplated by Amendment No. 2.
• The 8-K Filing will attach the form of Amendment No. 2 as an exhibit.
• The Company will issue two Additional Notes to investors.

Key Dates

Keywords

Note Purchase Agreement, Amendment, Aditxt, Ignite Proteomics, Senior Secured Notes, SEC Filing, Form 8-K, Financing